AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03825627 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total).
Study NCT01513343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent and child groups focused on self-regulation of eating
Study NCT00845104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT05522686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Brochure Education Group
Description: Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
Study NCT05522686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Video Education Group
Description: Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
Study NCT05522686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the Brochure-Supported Video Education Group
Description: Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
Study NCT05522686 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
Study NCT06235580 — intervention group
Intervention type: OTHER
Intervention: Biological Samples
Description: For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.
Study NCT05317572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.
Study NCT05317572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.
Study NCT05317572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 160 mcg intrathecal morphine
Description: İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg.
Study NCT03388372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
Study NCT03388372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
Study NCT03388372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
Study NCT00069641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iduronate-2-sulfatase enzyme replacement therapy
Description: Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
Study NCT03273777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing of an incision line
Description: Drawing of an incision line prior to skin incision at cesarean section
Study NCT01634893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with Hydroxychloroquine
Description: dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2.
Study NCT00069641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iduronate-2-sulfatase enzyme replacement therapy
Description: Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
Study NCT02014129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally
Study NCT00069641 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive weekly infusions of placebo.
Study NCT02186769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal® Consta®
Study NCT02186769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004
Study NCT01443845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast 500 µg, oral administration, once per day
Study NCT03766061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay mesh Hernioplasty
Description: Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
Study NCT03766061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sublay Mesh Hernioplasty
Description: Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleselumab
Description: Intravenous infusion
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Bolus injection
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Bolus injection
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Oral Intravenous
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Capsules
Description: Oral Capsule
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Capsules
Description: Oral Capsule
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Oral or Intravenous
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone
Description: Oral or Intravenous
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral Tablet
Study NCT02921789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral Tablet
Study NCT00639951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A
Description: 20 vials up front in a Single Dose of Antivipmyn
Study NCT00639951 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Antivipmyn ®
Description: 20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg/m\^2/day intravenous (IV) on Days 1-6
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincrisitne
Description: 1.5 mg/m\^2/day IV on Days 1 and 6
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: 30 mg/m\^2 IV over 24 hours on Day 5
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1 g/m\^2 IV over 36 hours on Day 1
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: 800 mg/m\^2 IV for 1 hour on Days 2-4
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-asparaginase
Description: 1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
Study NCT02393859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinia-asparaginase
Description: In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
Study NCT05065658 — intervention group
Intervention type: DRUG
Intervention: Posaconazole
Description: Intravenous posaconazole prophylaxis
Study NCT03697265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone (UC1010) low dose
Description: Subcutaneous (SC) administration
Study NCT03697265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepranolone (UC1010) high dose
Description: Subcutaneous (SC) administration
Study NCT03697265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) adminstration
Study NCT04093869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training combined with Exercise (CSTEX)
Description: The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
Study NCT00845104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00845104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT04093869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care plus Education (SOC-ED)
Description: The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
Study NCT00238875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Procedure/Surgery: stereotactic body radiation therapy
Study NCT03036774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of antral area
Description: Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures.
Study NCT03036774 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonic measurement of antral area
Description: Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures.
Study NCT01145131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact or minced beef meat
Description: 135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
Study NCT00210899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole medocaril
Study NCT00210899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin plus Ceftazidime
Study NCT01443845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo, oral administration, once per day.
Study NCT01477372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Description: Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
Study NCT03677349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neurorrhaphy
Description: During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1.
Study NCT03466021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
Study NCT01571596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
Study NCT04601129 — intervention group
Intervention type: PROCEDURE
Intervention: enhanced recovery after surgery program
Description: practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
Study NCT02764411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% gel
Description: Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
Study NCT00105534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite
Description: 1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
Study NCT00802464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine GSK1437173A
Description: 2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
Study NCT00105534 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
Study NCT04464239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: TS-142 tablets
Study NCT04464239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 Placebo
Description: TS-142 matching placebo tablets
Study NCT03466021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching injection
Study NCT00073814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol tartrate MDI
Description: levalbuterol MDI 90 mcg QID
Study NCT00073814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol MDI
Description: racemic albuterol MDI 180 mcg QID
Study NCT00802464 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 vaccinations at Months 0 and 2 with placebo
Study NCT00676325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of Anterior Vaginal Prolapse
Description: seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
Study NCT01437605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-A3 ASCI injections without Poly IC:LC
Description: MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
Study NCT01437605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAGE-A3 ASCI injections with Poly IC:LC
Description: MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
Study NCT05677061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw with HA-coating (Hiploc)
Description: During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
Study NCT05677061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Hip Screw without coating (Hiploc)
Description: During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
Study NCT00567333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chiropractic care
Description: A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.